MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze NVO →
    • FindStock Picks / Stock Screener
    • Value · NVOIntrinsic Value Calculator
    • Invest · NVOInvestment Case
    • Hold · NVO5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NVO stock logo

NVO

Novo Nordisk A/S

$41.63
0.98
 (2.41%)
Exchange:  NYSE
Market Cap:  184.446B
Shares Outstanding:  4.448B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Maziar Mike Doustdar
Full Time Employees:  68794
Address: 
Novo Alle 1
Bagsvaerd
CR
2880
DK
Website:  https://www.novonordisk.com
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company’s operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Click to read more…

Revenue Segmentation

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

NVO full analysis

08/11/2026

Welcome back to MarketSnap. Here's the contradiction I can't get past: Novo Nordisk just beat expectations, raised its guidance, and trades at a low-double-digit forward earnings multiple — and the stock has still lost nearly a third of its value over five years. So is that cheap price a gift, or a warning? Think about what a shareholder has lived through. This was the great GLP-1 growth story, the stock everyone wanted. Now it trades around forty dollars, down about…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
NVNVO logoNVONovo Nordisk A/S184.4B10.912.330.2%
PFPFE logoPFEPfizer Inc.164.7B40.99.58.3%
GIGILD logoGILDGilead Sciences, Inc.208.5B——28.0%
BMBMY logoBMYBristol-Myers Squibb Company129.7B14.09.914.9%
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%
SNSNY logoSNYSanofi115.9B25.110.77.5%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/04 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue232,261,000290,403,000309,064,000
Gross Profit196,496,000245,881,000250,276,000
EBITDA114,629,000147,938,000156,729,000
Operating Income102,574,000128,339,000127,658,000
Net Income83,683,000100,988,000102,434,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets314,486,000465,795,000542,902,000
Total Liabilities207,925,000322,309,000348,855,000
Total Stockholders Equity106,561,000143,486,000194,047,000
Total Debt27,006,000102,787,000130,958,000
Cash and Cash Equivalents14,392,00015,655,00026,464,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow108,908,000120,968,000114,528,195
Capital Expenditure-38,896,000-51,309,000-57,830,478
Free Cash Flow70,012,00069,659,00056,697,716
Net Income83,683,000100,988,000102,434,000
Net Change in Cash1,739,0001,263,00012,638,265

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)354,973,343.537Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)400,717,205.164Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)374,503,404.643Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)195,945,016.533Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)221,615,357.550Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)206,904,817.023Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)120,275,539.837Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)140,762,919.769Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)129,022,505.702Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)92,480,863.791Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)104,398,468.066Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)97,569,011.828Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)29.010Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)31.650Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)27.040Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)7Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
42.115B  ?P/S
 (TTM)
: 
3.68
?Net Income
 (TTM)
: 
14.646B  ?P/E
 (TTM)
: 
10.91
?Enterprise Value
 (TTM)
: 
1.318T  ?EV/FCF
 (TTM)
: 
28.34
?Dividend Yield
 (TTM)
: 
4.2%  ?Payout Ratio
 (TTM)
: 
45.85%
?ROE
 (TTM)
: 
54.14%  ?ROIC
 (TTM)
: 
30.19%
?Net Debt
 (TTM)
: 
10.62B  ?Debt/Equity
 (TTM)
: 
0.62
?P/B
 (TTM)
: 
5.63  ?Current Ratio
 (TTM)
: 
0.84

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
12.28Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Dominant oral GLP-1 position at a deep discount. Q3 2026 results showed adjusted sales up 4% to DKK 79.2B and adjusted operating profit up 27%, with free cash flow exceeding DKK 28B. The stock trades at roughly 7.8x trailing operating income and a TTM P/E of ~10.6x versus an industry average of ~44.8x, supporting a value thesis with projected annualized returns above 18% through 2030.
  • Exceptional profitability and balance-sheet capacity. Gross margin is 82.0%, net margin 33.9%, ROE 54.1%, and ROIC 32.9%. FY2025 free cash flow reached DKK 56.7B despite record capex of DKK 60.1B, and equity grew from DKK 143.5B (FY2024) to DKK 194.0B (FY2025).
  • Low volatility and income support. Beta of 0.35 and a 4.34% dividend yield (TTM) provide defensive characteristics and carry for long-term holders.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates NVO intrinsic value between $55.21 – $57.16 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate NVO Intrinsic Value

Common questions about NVO valuation

Is Novo Nordisk A/S (NVO) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Novo Nordisk A/S (NVO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NVO a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NVO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NVO’s P/E ratio?

You can see NVO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NVO?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NVO a good long-term investment?

Whether NVO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Novo Nordisk A/S

  • Novo Nordisk A/S intrinsic value calculatorEstimate what the business is worth
  • Novo Nordisk A/S 5-year outlookWhat has to go right, and what could go wrong
NVO

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

2.41
MarketSnap

Trading Metrics:

Open: 40.92   Previous Close: 40.65
Day Low: 40.64   Day High: 41.8
Year Low: 35.12   Year High: 64.16
Price Avg 50: 40.2   Price Avg 200: 43.27
Volume: 11.692M   Average Volume: 12.147M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Novo Nordisk: Better Than It Looks, But Not A Buy Yet
12-11-2026 05:42
Novo Nordisk: Better Than It Looks, But Not A Buy Yet
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
11-11-2026 21:15
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Novo Nordisk: Valuations Are Blind To The Upside
11-11-2026 18:21
Novo Nordisk: Valuations Are Blind To The Upside
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10-11-2026 10:01
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth
09-11-2026 02:56
Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income
06-11-2026 06:16
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze NVO →
    • FindStock Picks / Stock Screener
    • Value · NVOIntrinsic Value Calculator
    • Invest · NVOInvestment Case
    • Hold · NVO5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.